Gain access to the world’s largest and fastest growing cannabinoid medicines markets
Zelira Therapeutics offers investors exposure to a rapidly growing global industry at a very attractive valuation with significant value drivers.
Zelira’s revenue generation continues through multiple revenue streams from licensing payments, royalties and fast-tracking commercialisation through a disruptive ‘Launch, Learn & Develop’ model.
With a footprint in the US, Australia, UK and the EU, a portfolio of branded and validated products already launched, and a pipeline of Rx and OTC products underway, Zelira Therapeutics is well-positioned for continued growth.
For investor-related information please contact Ronn Bechler at Automic Group
Ph: +61 (0) 400 009 774 E: firstname.lastname@example.org